(152 days)
No
The description focuses on image comparison and analysis using traditional methods (DRR, CBCT comparison to CT) and does not mention AI/ML terms or describe training/testing of such models.
No
The device is a patient positioning and monitoring system used for accurate placement during radiation treatment, not for treating the condition itself.
No
Explanation: The device is described as a patient positioning and monitoring system for radiation therapy, focusing on accurate patient placement relative to the treatment beam. It uses imaging for positioning and monitoring, not for diagnosing diseases or conditions.
No
The device description explicitly states that ExacTrac is a "patient positioning and monitoring system" that utilizes "ExacTrac acquired X-ray images" and "a CBCT scan, acquired by a 30 Imaging Device". This indicates the system includes hardware components for image acquisition (X-ray and CBCT), which are not software-only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- ExacTrac's Function: ExacTrac is a patient positioning and monitoring system used in radiotherapy and radiosurgery. It uses imaging modalities (X-ray, CBCT, CT) to accurately position the patient for treatment and monitor their position during the procedure.
- Lack of Biological Sample Analysis: The description of ExacTrac's intended use and device description clearly indicates that it works with imaging data of the patient's body and does not involve the analysis of biological samples.
Therefore, ExacTrac falls under the category of medical devices used for treatment and monitoring, not in vitro diagnostics.
N/A
Intended Use / Indications for Use
ExacTrac is intended to be used to place patients at an accurately defined point within the treatment beam of a medical accelerator for stereotactic radiosurgery or radiotherapy procedures, in order to treat lesions, tumors and conditions anywhere in the body when radiation treatment is indicated. ExacTrac may also be used to monitor the patient position during the treatment.
Product codes
IYE
Device Description
ExacTrac is a patient positioning and monitoring system providing the following main features: Patient positioning based on comparison between ExacTrac acquired . X-ray images and calculated DRR (Digital Reconstructed Radiographs) using data provided by a treatment planning system. Patient positioning based on comparison between a CBCT scan, . acquired by a 30 Imaging Device and imported into ExacTrac, and CT data provided by a treatment planning system. Both modalities can be based on: anatomical landmarks 0 implanted markers 0 Patient monitoring during treatment .
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
X-ray, CBCT
Anatomical Site
anywhere in the body
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
For the Clinical Evaluation the following validation methods and data sources have been used: Literature review. Simulated treatment of anthropomorphic human-bone phantoms within a real clinical environment. Analysis of existing x-ray image datasets acquired with ExacTrac 5.5 during routine clinical use. Analysis of existing CBCT datasets during routine clinical use for retrospective clinical study.
Key Metrics
Not Found
Predicate Device(s)
ExacTrac 5.5 (K072506)
Reference Device(s)
Varian On-Board Imager Device (K042720)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.5050 Medical charged-particle radiation therapy system.
(a)
Identification. A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.(b)
Classification. Class II. When intended for use as a quality control system, the film dosimetry system (film scanning system) included as an accessory to the device described in paragraph (a) of this section, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
510 (K) SUMMARY OF SAFETY AND EFFECTIVENESS FOR EXACTRAC
AUG 1 4 2012 Manufacturer: Brainlab AG Kapellenstrasse 12 85622 Feldkirchen Germany Phone: +49 89 99 15 68 0 Fax: +49 89 99 15 68 33 Submitter: Rainer Birkenbach Contact person: Alexander Schwiersch June 11, 2012 Summary date: Device: ExacTrac ExacTrac® X-Ray, ExacTrac® Infrared Monitoring, ExacTrac® IGRT, Trade name: ExacTrac® Snap Verification, ExacTrac® Room-based IGRT, ExacTrac® CBCT Alignment Common/Classification Patient Positioning System with respiratory Gating, Radiation Therapy, Name: Charged-Particle, Medical ExacTrac 5.5 (K072506) Predicate Device: Varian On-Board Imager Device (K042720) Device classification System, Radiation Therapy, Charged-Particle, Medical name: Regulatory Class: Class II Regulation Number: 21 CFR 892.5050 Product Code: IYE ExacTrac is intended to be used to place patients at an accurately defined Indication for use point within the treatment beam of a medical accelerator for stereotactic radiosurgery or radiotherapy procedures, in order to treat lesions, tumors and conditions anywhere in the body when radiation treatment is indicated. ExacTrac may also,be used to monitor the patient position during the treatment. ExacTrac is a patient positioning and monitoring system providing the Device description: following main features: Patient positioning based on comparison between ExacTrac acquired . X-ray images and calculated DRR (Digital Reconstructed Radiographs) using data provided by a treatment planning system. Patient positioning based on comparison between a CBCT scan, . acquired by a 30 Imaging Device and imported into ExacTrac, and CT data provided by a treatment planning system.
- . Both modalities can be based on:
- anatomical landmarks 0
- implanted markers 0
- anatomical landmarks 0
- Patient monitoring during treatment .
FORM 04-195
REVISION 3
1
margins i.e. 4x or 8x its weight
- Heat resistance tests to make sure that the material does not change due . to a change in temperature e.g. as a result of sterilization
- . Biocompatibility tests
- Prototyping
- EMC testing in accredited laboratory .
Statement of the clinical test:
For the Clinical Evaluation the following validation methods and data sources have been used:
- � Literature review
- . Simulated treatment of anthropomorphic human-bone phantoms within a real clinical environment
- . Analysis of existing x-ray image datasets acquired with ExacTrac 5.5 during routine clinical use
- . Analysis of existing CBCT datasets during routine clinical use for retrospective clinical study.
Application performance testing
On different levels of development (module, subsystem, system) specific bench and integration tests were conducted. Internal standards were tested and documented as conformance report, environment compatibility and interfaces. Compatibility with previous version and comparable workflows to predicate devices were documented in corresponding review protocols.
Conclusions
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
2
Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or bird-like figure.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002
Mr. Alexander Schwiersch Regulatory Affairs Manager BrainLab AG R&D Radiosurgery Kapellenstrabe 12 FELDKIRCHEN BAVARIA 85622 GERMANY
AUG 1 4 2012
Re: K120789
Trade/Device Name: ExacTrac Regulation Number: 21 CFR 892.5050 Regulation Name: Medical charged-particle radiation therapy system Regulatory Class: II Product Code: IYE Dated: June 12, 2012 Received: June 18, 2012
Dear Mr. Schwiersch:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
3
medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the . Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely Yours,
Janine M. Morris
Acting Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
INDICATION FOR USE
510(k) Number (if known):
Device name: ExacTrac
Indication for use:
ExacTrac is intended to be used to place patients at an accurately defined point within the treatment beam of a medical accelerator for stereotactic radiosurgery or radiotherapy procedures, in order to treat lesions, tumors and conditions anywhere in the body when radiation treatment is indicated. ExacTrac may also be used to monitor the patient position during the treatment.
Prescription Use (Per 21 CFR 801 Subpart D). AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
.
Division Sign-Off
Division of Radiological Devices
510k K120789